Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CYBN Stock Forecast 2025-2026
$7.87
Current Price
$183.05M
Market Cap
Buy 7
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to CYBN Price Targets
+1,905.4%
To High Target of $157.82
+1,062.9%
To Median Target of $91.52
+231.3%
To Low Target of $26.08
CYBN Price Momentum
-12.6%
1 Week Change
-11.6%
1 Month Change
-21.8%
1 Year Change
-10.8%
Year-to-Date Change
-43.3%
From 52W High of $13.88
+63.6%
From 52W Low of $4.81
📊 TOP ANALYST CALLS
Did CYBN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Cybin is one of their latest high-conviction picks.
Latest CYBN Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, CYBN has a bullish consensus with a median price target of $91.52 (ranging from $26.08 to $157.82). The overall analyst rating is Strong Buy (9.7/10). Currently trading at $7.87, the median forecast implies a 1,062.9% upside. This outlook is supported by 7 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CYBN Analyst Ratings
7
Buy
0
Hold
0
Sell
CYBN Price Target Range
Low
$26.08
Average
$91.52
High
$157.82
Current: $7.87
Latest CYBN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CYBN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 13, 2025 | Guggenheim | Eddie Hickman | Buy | Initiates | $35.00 |
| Feb 13, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Maintains | $150.00 |
| Feb 12, 2025 | Canaccord Genuity | Sumant Kulkarni | Buy | Maintains | $73.00 |
| Jan 27, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $190.00 |
| Nov 19, 2024 | Canaccord Genuity | Sumant Kulkarni | Buy | Maintains | $86.00 |
| Nov 19, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $190.00 |
| Nov 18, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $190.00 |
| Nov 14, 2024 | Canaccord Genuity | Sumant Kulkarni | Buy | Maintains | $86.00 |
| Sep 23, 2024 | Canaccord Genuity | Sumant Kulkarni | Buy | Maintains | $96.00 |
| Aug 23, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $5.00 |
| Jul 31, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $5.00 |
| Jul 31, 2024 | Cantor Fitzgerald | Charles Duncan | Overweight | Reiterates | $0.00 |
| Jun 21, 2024 | Cantor Fitzgerald | Charles Duncan | Overweight | Reiterates | $0.00 |
| May 16, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $5.00 |
| Mar 13, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Maintains | $5.00 |
| Feb 15, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $5.00 |
| Nov 17, 2023 | HC Wainwright & Co. | Patrick Trucchio | Buy | Maintains | $5.00 |
| Oct 31, 2023 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $10.00 |
| Sep 1, 2023 | Canaccord Genuity | Sumant Kulkarni | Buy | Reiterates | $5.00 |
| Aug 30, 2023 | Oppenheimer | Francois Brisebois | Outperform | Reiterates | $4.00 |
Cybin Inc. (CYBN) Competitors
The following stocks are similar to Cybin based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Cybin Inc. (CYBN) Financial Data
Cybin Inc. has a market capitalization of $183.05M with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -57.5%.
Valuation Metrics
Market Cap
$183.05M
Enterprise Value
$29.55M
P/E Ratio
0.0x
PEG Ratio
-1.6x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+82.3%
Current Ratio
12.6x
Debt/Equity
0.0x
ROE
-57.5%
ROA
-44.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Cybin Inc. (CYBN) Business Model
About Cybin Inc.
What They Do
Advances psychedelic therapeutics for mental health.
Business Model
The company develops psychedelic-based medicines and engages in clinical trials and research programs. It generates revenue through partnerships with academic institutions and by leveraging proprietary technologies to enhance the efficacy of its products.
Additional Information
Cybin Inc. is positioned in the emerging psychedelic therapeutics market, focusing on innovative treatment solutions for psychological and neurological disorders. Its diverse delivery mechanisms, including sublingual, oral, and inhalative technologies, aim to improve patient outcomes and contribute to the growing investment in mental health treatment.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
50
CEO
Country
Canada
IPO Year
2019
Website
www.cybin.comCybin Inc. (CYBN) Latest News & Analysis
Latest News
Quick Summary
Cybin Inc. reported its audited financial results for the fiscal year ending March 31, 2025, highlighting ongoing efforts to enhance its neuropsychiatry treatment options.
Why It Matters
Cybin's financial results and business highlights indicate progress in its clinical developments, potentially impacting investor confidence and stock performance in the mental healthcare sector.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Cybin Inc. has signed a securities purchase agreement with High Trail Special Situations LLC to sell securities, aiming to advance its neuropsychiatry treatment options.
Why It Matters
Cybin's agreement to sell securities signals potential capital influx, which could finance its innovative mental health treatments, influencing future growth and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Cybin Inc. has signed a securities purchase agreement with High Trail Special Situations LLC to sell securities, aiming to advance its innovative mental healthcare treatments.
Why It Matters
Cybin's agreement to sell securities to High Trail indicates potential capital influx, which may enhance its ability to fund innovative treatments and drive growth in the neuropsychiatry sector.
Source: Business Wire
Market Sentiment:
Neutral
FDA seen likely to grant emergency use authorizations for psychedelics, boosting sector stocks
20 days ago
Quick Summary
The FDA may issue emergency use authorizations for psychedelics like psilocybin, reflecting a shift in regulatory attitude, potentially impacting investment in psychedelic therapies.
Why It Matters
The potential for FDA emergency use authorizations for psychedelics like psilocybin could lead to rapid market opportunities and increased investment in biotech and mental health sectors.
Source: Proactive Investors
Market Sentiment:
Positive
Quick Summary
Cybin Inc. CEO Doug Drysdale will speak at the Psychedelic Science 2025 Conference in Denver, June 16-20, 2025, highlighting the company's focus on innovative mental healthcare treatments.
Why It Matters
Cybin's CEO speaking at a major conference highlights the company's commitment to mental healthcare innovation, potentially boosting investor confidence and interest in its future growth.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Cybin Inc. (NYSE: CYBN) CEO Doug Drysdale will participate in a virtual fireside chat at the H.C. Wainwright Neuro Perspectives Conference on June 16-17, 2025.
Why It Matters
Cybin's CEO participation in a key industry conference signals potential for strategic partnerships and insights into mental health innovations, influencing investor sentiment and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About CYBN Stock
What is Cybin Inc.'s (CYBN) stock forecast for 2026?
Based on our analysis of 8 Wall Street analysts, Cybin Inc. (CYBN) has a median price target of $91.52. The highest price target is $157.82 and the lowest is $26.08.
Is CYBN stock a good investment in 2026?
According to current analyst ratings, CYBN has 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $7.87. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CYBN stock?
Wall Street analysts predict CYBN stock could reach $91.52 in the next 12 months. This represents a 1,062.9% increase from the current price of $7.87. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Cybin Inc.'s business model?
The company develops psychedelic-based medicines and engages in clinical trials and research programs. It generates revenue through partnerships with academic institutions and by leveraging proprietary technologies to enhance the efficacy of its products.
What is the highest forecasted price for CYBN Cybin Inc.?
The highest price target for CYBN is $157.82 from at , which represents a 1,905.4% increase from the current price of $7.87.
What is the lowest forecasted price for CYBN Cybin Inc.?
The lowest price target for CYBN is $26.08 from at , which represents a 231.3% increase from the current price of $7.87.
What is the overall CYBN consensus from analysts for Cybin Inc.?
The overall analyst consensus for CYBN is bullish. Out of 8 Wall Street analysts, 7 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $91.52.
How accurate are CYBN stock price projections?
Stock price projections, including those for Cybin Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 8, 2025 5:02 AM UTC